Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, ...
Aktis Oncology is seeking a valuation of as much as $840 million in its U.S. initial public offering, the biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback